Gabriel Nowak

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3832551/publications.pdf

Version: 2024-02-01

216 papers	8,225 citations	41258 49 h-index	71532 76 g-index
224 all docs	224 docs citations	224 times ranked	7266 citing authors

#	Article	IF	Citations
1	New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidatesâ€"Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 2012, 20, 127-150.	1.9	285
2	Alterations in the N-methyl-d-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Research, 1995, 675, 157-164.	1.1	277
3	Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study. Journal of Affective Disorders, 2009, 118, 187-195.	2.0	176
4	Mood disorders: Regulation by metabotropic glutamate receptors. Biochemical Pharmacology, 2008, 75, 997-1006.	2.0	164
5	Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Research Bulletin, 2003, 61, 159-164.	1.4	153
6	The efficacy of zinc supplementation in depression: Systematic review of randomised controlled trials. Journal of Affective Disorders, 2012, 136, e31-e39.	2.0	143
7	The role of zinc in neurodegenerative inflammatory pathways in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 693-701.	2.5	139
8	Antidepressant-like properties of zinc in rodent forced swim test. Brain Research Bulletin, 2001, 55, 297-300.	1.4	137
9	Biological consequences of zinc deficiency in the pathomechanisms of selected diseases. Journal of Biological Inorganic Chemistry, 2014, 19, 1069-1079.	1.1	127
10	Essential elements in depression and anxiety. Part I. Pharmacological Reports, 2014, 66, 534-544.	1.5	122
11	The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 323-329.	2.5	117
12	Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. Journal of Affective Disorders, 2010, 126, 447-452.	2.0	111
13	Antidepressant-like activity of zinc: further behavioral and molecular evidence. Journal of Neural Transmission, 2008, 115, 1621-1628.	1.4	110
14	Oxidative stress markers in affective disorders. Pharmacological Reports, 2013, 65, 1558-1571.	1.5	110
15	Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Polish Journal of Pharmacology, 2003, 55, 1143-7.	0.3	107
16	Zinc and depression. An update. Pharmacological Reports, 2005, 57, 713-8.	1.5	106
17	Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacological Reports, 2008, 60, 588-9.	1.5	105
18	Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacology Biochemistry and Behavior, 2004, 78, 7-12.	1.3	104

#	Article	IF	Citations
19	(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 659-663.	2.5	92
20	Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology, 2004, 47, 342-350.	2.0	87
21	Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. European Journal of Pharmacology, 1993, 247, 305-311.	2.7	86
22	Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 372-383.	2.5	82
23	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. European Journal of Medicinal Chemistry, 2013, 60, 42-50.	2.6	81
24	Zinc deficiency induces behavioral alterations in the tail suspension test in mice. Effect of antidepressants. Pharmacological Reports, 2012, 64, 249-255.	1.5	80
25	The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids, 2010, 39, 205-217.	1.2	77
26	The influence of the route of administration of gold nanoparticles on their tissue distribution and basic biochemical parameters: In vivo studies. Pharmacological Reports, 2015, 67, 405-409.	1.5	77
27	Antidepressant drugs given repeatedly increase binding to Î±1-adrenoceptors in the rat cortex. European Journal of Pharmacology, 1985, 119, 113-116.	1.7	73
28	Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology, 2008, 198, 421-430.	1.5	73
29	GABA-ergic hypotheses of anxiety and depression: Focus on GABA-B receptor. Drugs of Today, 2005, 41, 755.	0.7	72
30	Down-regulation of cortical Î²-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology, 1992, 106, 285-287.	1.5	70
31	Alterations in serum and brain trace element levels after antidepressant treatment. Biological Trace Element Research, 1999, 67, 85-92.	1.9	70
32	Magnesium in depression. Pharmacological Reports, 2013, 65, 547-554.	1.5	70
33	NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacology Biochemistry and Behavior, 2007, 88, 158-164.	1.3	69
34	Zinc as a marker of affective disorders. Pharmacological Reports, 2013, 65, 1512-1518.	1.5	66
35	The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims. Neuropharmacology, 2014, 79, 290-297.	2.0	66
36	GPR39 (Zinc Receptor) Knockout Mice Exhibit Depression-Like Behavior and CREB/BDNF Down-Regulation in the Hippocampus. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	66

#	Article	IF	Citations
37	Zinc treatment induces cortical brain-derived neurotrophic factor gene expression. European Journal of Pharmacology, 2004, 492, 57-59.	1.7	63
38	Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. Journal of Affective Disorders, 2013, 151, 924-931.	2.0	63
39	Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. Pharmacological Reports, 2012, 64, 567-575.	1.5	62
40	Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor. Neuropharmacology, 2015, 99, 301-307.	2.0	61
41	Zinc, future mono/adjunctive therapy for depression: Mechanisms of antidepressant action. Pharmacological Reports, 2015, 67, 659-662.	1.5	60
42	Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacological Reports, 2006, 58, 571-6.	1.5	60
43	Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. European Journal of Pharmacology, 1996, 295, 75-85.	1.7	58
44	Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity. Neural Plasticity, 2017, 2017, 1-18.	1.0	58
45	Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1208-1225.	1.3	57
46	Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia. Neurotoxicity Research, 2018, 33, 448-460.	1.3	57
47	The role of the GPR39 receptor in zinc deficient-animal model of depression. Behavioural Brain Research, 2013, 238, 30-35.	1.2	56
48	Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on GABAergic system. European Journal of Medicinal Chemistry, 2014, 86, 690-699.	2.6	56
49	Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. European Journal of Pharmacology, 1998, 342, 367-370.	1.7	55
50	Antidepressant-like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits. International Journal of Neuropsychopharmacology, 2014, 17, 393-405.	1.0	54
51	Zinc signaling and epilepsy. , 2019, 193, 156-177.		52
52	Development of the 1,2,4-triazole-based anticonvulsant drug candidates acting on the voltage-gated sodium channels. Insights from in-vivo, in-vitro, and in-silico studies. European Journal of Pharmaceutical Sciences, 2019, 129, 42-57.	1.9	52
53	Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence. Neuropharmacology, 2000, 39, 2278-2287.	2.0	49
54	Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors. Pharmacological Reports, 2009, 61, 1184-1191.	1.5	49

#	Article	IF	Citations
55	A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. Journal of Neural Transmission, 2011, 118, 1535-1546.	1.4	46
56	Study of the Serum Copper Levels in Patients with Major Depressive Disorder. Biological Trace Element Research, 2016, 174, 287-293.	1.9	46
57	Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder. Molecular Neurobiology, 2017, 54, 5883-5893.	1.9	46
58	Serum trace elements in animal models and human depression. Part I. Zinc. , 1999, 14, 83-86.		45
59	Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. Pharmacological Reports, 2006, 58, 746-52.	1.5	45
60	Serum trace elements in animal models and human depression: Part III. Magnesium. Relationship with copper. Human Psychopharmacology, 2000, 15, 631-635.	0.7	44
61	Investigational NMDA receptor modulators for depression. Expert Opinion on Investigational Drugs, 2012, 21, 91-102.	1.9	44
62	Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway. Psychopharmacology, 2015, 232, 355-367.	1.5	44
63	Chronic unpredictable stress-induced reduction in the hippocampal brain-derived neurotrophic factor (BDNF) gene expression is antagonized by zinc treatment. Pharmacological Reports, 2011, 63, 537-543.	1.5	43
64	Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 254-263.	2.5	43
65	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. European Journal of Medicinal Chemistry, 2010, 45, 1295-1303.	2.6	42
66	NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacological Reports, 2010, 62, 1186-1190.	1.5	42
67	Interaction of zinc with antidepressants in the forced swimming test in mice. Polish Journal of Pharmacology, 2002, 54, 681-5.	0.3	42
68	NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs, 2014, 23, 1181-1192.	1.9	40
69	Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc. Neuropharmacology, 2015, 99, 517-526.	2.0	40
70	Phospholipid-protein balance in affective disorders: Analysis of human blood serum using Raman and FTIR spectroscopy. A pilot study. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 287-296.	1.4	40
71	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. Molecular Neurobiology, 2016, 53, 2927-2935.	1.9	40
72	Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice. Pharmacology Biochemistry and Behavior, 2005, 81, 524-529.	1.3	39

#	Article	IF	Citations
73	The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at Î±1 Subunit-Containing GABAA Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1244-1252.	1.3	39
74	Relationship between Zinc (Zn2+) and Glutamate Receptors in the Processes Underlying Neurodegeneration. Neural Plasticity, 2015, 2015, 1-9.	1.0	39
75	An update on NMDA antagonists in depression. Expert Review of Neurotherapeutics, 2019, 19, 1055-1067.	1.4	39
76	GPR39 Zn2+-sensing receptor: A new target in antidepressant development?. Journal of Affective Disorders, 2015, 174, 89-100.	2.0	38
77	Swim Stress Increases the Potency of Glycine at the N-Methyl-d-Aspartate Receptor Complex. Journal of Neurochemistry, 2002, 64, 925-927.	2.1	36
78	The serum zinc concentration as a potential biological marker in patients with major depressive disorder. Metabolic Brain Disease, 2017, 32, 97-103.	1.4	36
79	Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacological Reports, 2013, 65, 991-997.	1.5	35
80	Studies on the Anticonvulsant Activity and Influence on GABA-ergic Neurotransmission of 1,2,4-Triazole-3-thione- Based Compounds. Molecules, 2014, 19, 11279-11299.	1.7	35
81	Effects of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacological Reports, 2005, 57, 654-8.	1.5	35
82	Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 359, 280-287.	1.4	34
83	Pharmacological Profile of the â€œTripleâ€•Monoamine Neurotransmitter Uptake Inhibitor, DOV 102,677. Cellular and Molecular Neurobiology, 2006, 26, 855-871.	1.7	34
84	GPR39 up-regulation after selective antidepressants. Neurochemistry International, 2013, 62, 936-939.	1.9	34
85	Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacological Reports, 2006, 58, 427-30.	1.5	34
86	Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives asÂpotential antidepressant agents. Part 1. European Journal of Medicinal Chemistry, 2013, 63, 484-500.	2.6	33
87	Lower Serum Zinc and Higher CRP Strongly Predict Prenatal Depression and Physio-somatic Symptoms, Which All Together Predict Postnatal Depressive Symptoms. Molecular Neurobiology, 2017, 54, 1500-1512.	1.9	33
88	Antidepressant-like activity of hyperforin and changes in BDNF and zinc levels in mice exposed to chronic unpredictable mild stress. Behavioural Brain Research, 2019, 372, 112045.	1.2	33
89	Anxiolytic-like activity of zinc in rodent tests. Pharmacological Reports, 2011, 63, 1050-1055.	1.5	32
90	NMDA and AMPA receptors are involved in the antidepressant-like activity of tianeptine in the forced swim test in mice. Pharmacological Reports, 2011, 63, 1526-1532.	1.5	32

#	Article	IF	Citations
91	Zinc deficiency alters responsiveness to antidepressant drugs in mice. Pharmacological Reports, 2013, 65, 579-592.	1.5	32
92	Identification of Novel Serotonin Transporter Compounds by Virtual Screening. Journal of Chemical Information and Modeling, 2014, 54, 933-943.	2.5	32
93	Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats. Neuropharmacology, 2017, 125, 333-342.	2.0	32
94	Targeting zinc metalloenzymes in coronavirus disease 2019. British Journal of Pharmacology, 2020, 177, 4887-4898.	2.7	32
95	Alterations in hippocampal calcium-binding neurons induced by stress models of depression: a preliminary assessment. Pharmacological Reports, 2010, 62, 1204-1210.	1.5	31
96	Antidepressant-like effect of chromium chloride in the mouse forced swim test: involvement of glutamatergic and serotonergic receptors. Pharmacological Reports, 2008, 60, 991-5.	1.5	31
97	Study of antidepressant drugs in GPR39 (zinc receptorâ^'/â^') knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists. Behavioural Brain Research, 2015, 287, 135-138.	1.2	30
98	Concentration-Dependent Dual Mode of Zn Action at Serotonin 5-HT1A Receptors: In Vitro and In Vivo Studies. Molecular Neurobiology, 2016, 53, 6869-6881.	1.9	30
99	Alterations of Bio-elements, Oxidative, and Inflammatory Status in the Zinc Deficiency Model in Rats. Neurotoxicity Research, 2016, 29, 143-154.	1.3	30
100	Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacological Reports, 2007, 59, 595-600.	1.5	30
101	Thiobarbituric Acid-Reactive Substances: Markers of an Acute Episode and a Late Stage of Bipolar Disorder. Neuropsychobiology, 2016, 73, 116-122.	0.9	29
102	Zinc transporters protein level in postmortem brain of depressed subjects and suicide victims. Journal of Psychiatric Research, 2016, 83, 220-229.	1.5	29
103	Hyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice. Frontiers in Molecular Neuroscience, 2018, 11, 456.	1.4	29
104	New Arylpiperazine 5-HT1AReceptor Ligands Containing the Pyrimido[2,1-f]purine Fragment:Â Synthesis, in Vitro, and in Vivo Pharmacological Evaluation. Journal of Medicinal Chemistry, 2004, 47, 2659-2666.	2.9	28
105	Preclinical evaluation of 1,2,4-triazole-based compounds targeting voltage-gated sodium channels (VGSCs) as promising anticonvulsant drug candidates. Bioorganic Chemistry, 2020, 94, 103355.	2.0	28
106	Antidepressant activity of fluoxetine in the zinc deficiency model in rats involves the NMDA receptor complex. Behavioural Brain Research, 2015, 287, 323-330.	1.2	27
107	Potential antidepressant-like properties of the TC G-1008, a GPR39 (zinc receptor) agonist. Journal of Affective Disorders, 2016, 201, 179-184.	2.0	27
108	Decreased serum zinc concentration during depressive episode in patients with bipolar disorder. Journal of Affective Disorders, 2016, 190, 272-277.	2.0	27

#	Article	IF	Citations
109	EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors. European Journal of Pharmacology, 1988, 153, 309-311.	1.7	25
110	Lack of NMDAâ€“AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. Journal of Neural Transmission, 2008, 115, 1519-1520.	1.4	25
111	Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 29-35.	2.5	25
112	NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice. Pharmacological Reports, 2008, 60, 655-63.	1.5	25
113	Effect of repeated treatment with electroconvulsive shock (ECS) on serotonin receptor density and turnover in the rat cerebral cortex. Pharmacology Biochemistry and Behavior, 1991, 38, 691-694.	1.3	24
114	Different pattern of changes in calcium binding proteins immunoreactivity in the medial prefrontal cortex of rats exposed to stress models of depression. Pharmacological Reports, 2011, 63, 1539-1546.	1.5	24
115	Stress-induced alterations in 5-HT1A receptor transcriptional modulators NUDR and Freud-1. International Journal of Neuropsychopharmacology, 2014, 17, 1763-1775.	1.0	24
116	Up-regulation of the GPR39 Zn(2+)-sensing receptor and CREB/BDNF/TrkB pathway after chronic but not acute antidepressant treatment in the frontal cortex of zinc-deficient mice. Pharmacological Reports, 2015, 67, 1135-1140.	1.5	24
117	The role of magnesium and zinc in depression: similarities and differences. Magnesium Research, 2018, 31, 78-89.	0.4	24
118	D-serine, a selective glycine/N-methyl-D-aspartate receptor agonist, antagonizes the antidepressant-like effects of magnesium and zinc in mice. Pharmacological Reports, 2008, 60, 996-1000.	1.5	24
119	Chronic treatment with zinc and antidepressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortex. Amino Acids, 2011, 40, 249-258.	1.2	23
120	Long-lasting antidepressant-like activity of the GPR39 zinc receptor agonist TC-G 1008. Journal of Affective Disorders, 2019, 245, 325-334.	2.0	23
121	Epigenetic marks and their relationship with BDNF in the brain of suicide victims. PLoS ONE, 2020, 15, e0239335.	1.1	23
122	Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents. Neurotoxicity Research, 2017, 32, 544-554.	1.3	22
123	Mechanisms contributing to antidepressant zinc actions. Polish Journal of Pharmacology, 2002, 54, 587-92.	0.3	22
124	Beneficial effect of nanoparticles over standard form of zinc oxide in enhancing the anti-inflammatory activity of ketoprofen in rats. Pharmacological Reports, 2017, 69, 679-682.	1.5	21
125	Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect. European Journal of Medicinal Chemistry, 2019, 183, 111736.	2.6	21
126	Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Polish Journal of Pharmacology, 2003, 55, 455-9.	0.3	20

#	Article	IF	Citations
127	Alterations in Serum and Brain Trace Element Levels After Antidepressant Treatment. Part II. Copper. Biological Trace Element Research, 2000, 73, 37-46.	1.9	19
128	Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. part 3. European Journal of Medicinal Chemistry, 2011, 46, 142-149.	2.6	19
129	Evaluation of anti-inflammatory and ulcerogenic potential of zincâ€“ibuprofen and zincâ€“naproxen complexes in rats. Inflammopharmacology, 2017, 25, 653-663.	1.9	19
130	Molecular mechanism of action and safety of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione - a novel anticonvulsant drug candidate. International Journal of Medical Sciences, 2017, 14, 741-749.	1.1	19
131	Increase in synaptic hippocampal zinc concentration following chronic but not acute zinc treatment in rats. Brain Research, 2006, 1090, 69-75.	1.1	18
132	Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, Part 1. European Journal of Medicinal Chemistry, 2009, 44, 1710-1717.	2.6	18
133	Tissue distribution of gold nanoparticles after single intravenous administration in mice. Pharmacological Reports, 2013, 65, 1033-1038.	1.5	18
134	Pregabalin for the treatment of social anxiety disorder. Expert Opinion on Investigational Drugs, 2015, 24, 585-594.	1.9	18
135	The serum concentration of copper in bipolar disorder. Psychiatria Polska, 2017, 51, 469-481.	0.2	18
136	Ca2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex. European Journal of Pharmacology, 1993, 247, 101-102.	2.7	17
137	Olfactory bulbectomy-induced changes in phospholipids and protein profiles in the hippocampus and prefrontal cortex of rats. A preliminary study using a FTIR spectroscopy. Pharmacological Reports, 2016, 68, 521-528.	1.5	17
138	Synthesis and 5-HT1A, 5-HT2A receptor activity of new Î²-tetralonohydantoins. European Journal of Medicinal Chemistry, 2005, 40, 820-829.	2.6	16
139	Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives. European Journal of Medicinal Chemistry, 2009, 44, 4288-4296.	2.6	16
140	Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice. Journal of Neural Transmission, 2011, 118, 857-864.	1.4	16
141	Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 5. European Journal of Medicinal Chemistry, 2015, 98, 221-236.	2.6	16
142	Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response. Nutrients, 2018, 10, 1014.	1.7	16
143	The effect of repeated treatment with brofaromine, moclobemide and deprenyl on Î±1-adrenergic and dopaminergic receptors in the rat brain. Neuroscience Letters, 1990, 108, 189-194.	1.0	15
144	Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity: Part 2â˜†. European Journal of Medicinal Chemistry, 2009, 44, 4702-4715.	2.6	15

#	Article	IF	Citations
145	Biochemical and pharmacological tests for the prediction of ability of monoamine uptake blockers to inhibit the uptake of noradrenaline in-vivo: the effects of desipramine, maprotiline, femoxetine and citalopramFn fn1. Journal of Pharmacy and Pharmacology, 2011, 39, 1003-1009.	1.2	15
146	Prolonged administration of antidepressant drugs leads to increased binding of [3H]MPEP to mGlu5 receptors. Neuropharmacology, 2014, 84, 46-51.	2.0	15
147	Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 4. European Journal of Medicinal Chemistry, 2015, 90, 21-32.	2.6	15
148	Repeated electroconvulsive shock (ECS) enhances striatal D-1 dopamine receptor turnover in rats. European Journal of Pharmacology, 1989, 167, 307-308.	1.7	14
149	Synthesis ofÂnew hexahydro- andÂoctahydropyrido[1,2-c]pyrimidine derivatives with anÂarylpiperazine moiety asÂligands forÂ5-HT1A andÂ5-HT2A receptors. Part 4. European Journal of Medicinal Chemistry, 2006, 41, 125-134.	2.6	14
150	Evaluation of oxidative status and depression-like responses in Brown Norway rats with acute myeloid leukemia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 596-604.	2.5	14
151	Evaluation of the role of NMDA receptor function in antidepressant-like activity. A new study with citalopram and fluoxetine in the forced swim test in mice. Pharmacological Reports, 2015, 67, 490-493.	1.5	14
152	The level of the zinc homeostasis regulating proteins in the brain of rats subjected to olfactory bulbectomy model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 36-48.	2.5	14
153	Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. European Journal of Medicinal Chemistry, 2019, 166, 144-158.	2.6	14
154	Age-dependent day/night variations of Î±1- and Î²-adrenoceptors in the rat cerebral cortex. Physiology and Behavior, 1986, 38, 53-55.	1.0	13
155	[3H]1-aminocyclopropanecarboxylic acid, a novel probe for strychnine-insensitive glycine receptors. European Journal of Pharmacology, 1995, 291, 221-227.	2.7	13
156	Serum trace elements in animal models and human depression. Part II. Copper. , 1999, 14, 447-451.		13
157	Neuroimmunological aspects of the alterations in zinc homeostasis in the pathophysiology and treatment of depression. Acta Neuropsychiatrica, 2000, 12, 49-53.	1.0	13
158	Antidepressant-like activity of 8-Br-cAMP, a PKA activator, in the forced swim test. Journal of Neural Transmission, 2008, 115, 829-830.	1.4	13
159	Allosteric Inhibition of Serotonin 5-HT7 Receptors by Zinc Ions. Molecular Neurobiology, 2018, 55, 2897-2910.	1.9	13
160	The serum concentration of magnesium as a potential state marker in patients with diagnosis of bipolar disorder. Psychiatria Polska, 2015, 49, 1277-1287.	0.2	13
161	Chronic imipramine treatment upregulates IR2-imidazoline receptive sites in rat brain. Neurochemistry International, 1997, 30, 101-107.	1.9	12
162	Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1. European Journal of Medicinal Chemistry, 2011, 46, 4474-4488.	2.6	12

#	Article	IF	Citations
163	The effects of ifenprodil on the activity of antidepressant drugs in the forced swim test in mice. Pharmacological Reports, 2014, 66, 1031-1036.	1.5	12
164	7-3-Chlorophenypiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione as a serotonin receptor ligands with potential antidepressant activity. Pharmacological Reports, 2014, 66, 505-510.	1.5	12
165	Ergotamine and nicergoline â€“ Facts and myths. Pharmacological Reports, 2015, 67, 360-363.	1.5	12
166	Immune malfunction in the GPR39 zinc receptor of knockout mice: Its relationship to depressive disorder. Journal of Neuroimmunology, 2016, 291, 11-17.	1.1	12
167	Acid sphingomyelinase â€“ a regulator of canonical transient receptor potential channel 6 (TRPC6) activity. Journal of Neurochemistry, 2019, 150, 678-690.	2.1	12
168	Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action. Nutrients, 2020, 12, 2529.	1.7	12
169	Down-regulation of dopamine1 (D1) receptors by chronic imipramine is species-specific. Pharmacology Biochemistry and Behavior, 1991, 39, 769-771.	1.3	11
170	Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. European Journal of Medicinal Chemistry, 2019, 180, 383-397.	2.6	11
171	Synthesis of new 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives and evaluation for their 5-HT1A and D2 receptor affinity and serotonin transporter inhibition. Bioorganic Chemistry, 2020, 97, 103662.	2.0	11
172	Interaction between zinc, the GPR39 zinc receptor and the serotonergic system in depression. Brain Research Bulletin, 2021, 170, 146-154.	1.4	11
173	Synthesis of new hexahydro- and octahydropyrido[1,2-c]pyrimidine derivatives with an arylpiperazine moiety as ligands for 5-HT1A and 5-HT2A receptors. Il Farmaco, 2002, 57, 959-971.	0.9	10
174	Synthesis, Antidepressant Evaluation and Docking Studies of Longâ€Chain Alkylnitroquipazines as Serotonin Transporter Inhibitors. Chemical Biology and Drug Design, 2013, 81, 695-706.	1.5	10
175	The serum magnesium concentration as a potential state marker in patients with unipolar affective disorder. Psychiatria Polska, 2015, 49, 1265-1276.	0.2	10
176	N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible receptor inactivator, as a tool for measurement of Î±2-adrenoceptor occupancy in vivo. European Journal of Pharmacology, 1992, 212, 109-111.	1.7	9
177	Early lifetime zinc supplementation protects zinc-deficient diet-induced alterations. Pharmacological Reports, 2010, 62, 1211-1217.	1.5	9
178	Evaluation of anticonvulsant activity of novel pyrrolidin-2-one derivatives. Pharmacological Reports, 2014, 66, 708-711.	1.5	9
179	Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors. European Journal of Pharmacology, 2000, 389, 187-192.	1.7	8
180	The molecular interactions of buspirone analogues with the serotonin transporter. Bioorganic and Medicinal Chemistry, 2008, 16, 9283-9294.	1.4	8

#	Article	IF	Citations
181	An anti-immobility effect of spermine in the forced swim test in mice. Pharmacological Reports, 2014, 66, 223-227.	1.5	8
182	Synthesis and biological investigation of new equatorial (Î²) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile. Bioorganic and Medicinal Chemistry, 2016, 24, 3994-4007.	1.4	8
183	Synthesis of Novel Pyrido[1,2-c]pyrimidine Derivatives with 6-Fluoro-3-(4-piperidynyl)-1,2-benzisoxazole Moiety as Potential SSRI and 5-HT1A Receptor Ligands. International Journal of Molecular Sciences, 2021, 22, 2329.	1.8	8
184	The importance of timing for the action of Î±1- or Î²-agonists: Possible relationship with the density of [3H]prazosin and [3H]dihydroalprenolol binding sites. European Journal of Pharmacology, 1985, 113, 279-282.	1.7	7
185	Role of Dopaminergic Neurons in Denervation-Induced ?1-Adrenergic Up-Regulation in the Rat Cerebral Cortex. Journal of Neurochemistry, 1991, 56, 914-916.	2.1	7
186	Brain glutamic acid decarboxylase-67kDa alterations induced by magnesium treatment in olfactory bulbectomy and chronic mild stress models in rats. Pharmacological Reports, 2016, 68, 881-885.	1.5	7
187	GPCR oligomerization as a target for antidepressants: Focus on GPR39. , 2021, 225, 107842.		7
188	Chronic treatment with zinc hydroaspartate induces anti-inflammatory and anti-ulcerogenic activity in rats. Pharmacological Reports, 2014, 66, 862-866.	1.5	6
189	The Possibilities of Using Chromium Salts as an Agent Supporting Treatment of Polycystic Ovary Syndrome. Biological Trace Element Research, 2019, 192, 91-97.	1.9	6
190	Zinc and copper concentration do not differentiate bipolar disorder from major depressive disorder. Psychiatria Polska, 2018, 52, 449-457.	0.2	6
191	Kinetics of [3H]-prazosin binding to the rat cortex during aging. Pharmacology Biochemistry and Behavior, 1988, 31, 505-507.	1.3	5
192	Synthesis, inÂvitro binding studies and docking of long-chain arylpiperazine nitroquipazine analogues, as potential serotonin transporter inhibitors. European Journal of Medicinal Chemistry, 2012, 49, 200-210.	2.6	5
193	Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction. International Journal of Molecular Sciences, 2020, 21, 4791.	1.8	5
194	Medium supplementation with zinc enables detection of imipramine-induced adaptation in glycine/NMDA receptors labeled with [3H]L-689,560. Pharmacological Reports, 2006, 58, 753-7.	1.5	5
195	Antidepressant-like Effects of Combined Fluoxetine and Zinc Treatment in Mice Exposed to Chronic Restraint Stress Are Related to Modulation of Histone Deacetylase. Molecules, 2022, 27, 22.	1.7	5
196	Alterations of Serum Magnesium Concentration in Animal Models of Seizures and Epilepsyâ€"The Effects of Treatment with a GPR39 Agonist and Knockout of the Gpr39 Gene. Cells, 2022, 11, 1987.	1.8	5
197	The Turnover of Rat Cortical ?1-Adrenoceptors Is Not Modified by Repeated Electroconvulsive Treatment. Journal of Neurochemistry, 1991, 56, 2004-2006.	2.1	4
198	Effect of Repeated Treatment with Antidepressant Drugs and Electroconvulsive Shock (ECS) on the D₂ Dopaminergic Receptor Turnover in the Rat Brain*. Basic and Clinical Pharmacology and Toxicology, 1991, 69, 87-89.	0.0	4

#	Article	IF	Citations
199	Ionic Glutamate Modulators in Depression (Zinc, Magnesium). , 2010, , 21-38.		4
200	Longâ€Term Effect of Antidepressant Drugs and Electroconvulsive Shock (ECS) on Cortical Î±₁â€Adrenoceptors Following Destruction of Dopaminergic Nerve Terminals. Basic and Clinical Pharmacology and Toxicology, 1989, 64, 469-470.	0.0	3
201	Effect of Depression and of Antidepressant Therapy on Serum Zinc Levels. , 2002, , 607-610.		3
202	A bright future of researching AMPA receptor agonists for depression treatment. Expert Opinion on Investigational Drugs, 2012, 21, 583-585.	1.9	3
203	Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways. Neurotoxicity Research, 2021, 39, 170-181.	1.3	3
204	Corrigendum to: â€œNoradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptorsâ€•[Eur. J. Pharmacol. 389 (2000) 187â€“192]. European Journal of Pharmacology, 2000, 397, 399.	1.7	2
205	Serotonin transporter activity of imidazolidine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives in aspect of their acidâ€“base properties. Medicinal Chemistry Research, 2012, 21, 3455-3459.	1.1	2
206	Depression Viewed as a GABA/Glutamate Imbalance in the Central Nervous System. , 0, , .		2
207	Pharmaco-Electroencephalography-Based Assessment of Antidepressant Drug Efficacyâ€”The Use of Magnesium Ions in the Treatment of Depression. Journal of Clinical Medicine, 2021, 10, 3135.	1.0	2
208	Zinc Deficiency Blunts the Effectiveness of Antidepressants in the Olfactory Bulbectomy Model of Depression in Rats. Nutrients, 2022, 14, 2746.	1.7	2
209	Zinc Deficiency and Depression. , 0, , .		1
210	Differential effect of nanoparticle and standard forms of ZnO on serum zinc and magnesium levels in rats. Magnesium Research, 2018, 31, 58-64.	0.4	1
211	Analysis of Density Changes of Selected Brain Receptors After a 14-Day Supply of Chromium(III) and Evaluation of Chromium(III) Affinity to Selected Receptors and Transporters. Biological Trace Element Research, 2020, 196, 359-364.	1.9	1
212	Role of Neurotoxicity in Depression. , 2014, , 1567-1593.		1
213	Metabotropic Approaches to Anxiety. , 2010, , 157-173.		1
214	Synthesis of New Hexahydro- and Octahydropyrido[1,2-c]pyrimidine Derivatives with an Arylpiperazine Moiety as Ligands for 5-HT1A and 5-HT2A Receptors.. ChemInform, 2003, 34, no.	0.1	0
215	Synthesis and 5-HT1A, 5-HT2A Receptor Activity of New Î²-Tetralonohydantoins.. ChemInform, 2006, 37, no.	0.1	0
216	Neurotoxicity in Depression. , 2021, , 1-30.		0